FDA Outlines Regulatory Expectations for Digital Tools Targeting Behavioral Health and Mindfulness

The FDA applies its existing policies to software that claims effects on behavioral health or mindfulness. Tools making specific claims to treat or mitigate conditions like anxiety fall under medical device rules. Those limited to general wellness typically do not. The agency coordinates these reviews through its Digital Health Center of Excellence.

What this means

The policies draw a line between apps that require formal evidence of safety and effectiveness and those that do not. Developers of behavioral health tools now have clearer signals on when their marketing language triggers oversight. This affects how such products reach users and the type of data companies must generate.

Key takeaways

• Software functions intended to treat, diagnose, cure, mitigate, or prevent disease or conditions are medical devices subject to FDA regulation. [1]
• Stress-management claims that rise to medical intent trigger oversight. Pure wellness claims do not. [1]
• The FDA established its Digital Health Center of Excellence in 2020 to advance safe innovation while protecting public health. [2]
• Digital therapeutics making specific disorder treatment claims require FDA review. [1][2]
• NIH statistics supply prevalence context on anxiety and related conditions that many digital tools target. [3]

The FDA classifies digital products according to their intended use. One 2019 guidance document states that any software function with medical intent meets the legal definition of a device. [1] This includes certain behavioral health apps that name particular psychiatric conditions.

Claims matter. An app that says it reduces everyday stress occupies a different category from one that says it treats an anxiety disorder. The first usually stays outside FDA oversight. The second requires developers to meet regulatory standards for safety and performance. [1]

The agency set up a dedicated office to handle the surge in these products. The Digital Health Center of Excellence opened in 2020. It works to align review processes for software as a medical device, including tools aimed at mental health. [2]

Interest in these tools tracks broader health patterns. The National Institute of Mental Health tracks data on anxiety disorders, which remain common. [3] That background helps explain why so many developers build digital products in this space.

FDA policies rely on risk. Higher-risk behavioral health claims demand stronger clinical data. Lower-risk wellness functions face lighter review. The agency also weighs cybersecurity and real-world performance when it evaluates mental health software. [2]

Limitations

No single FDA guidance document is dedicated exclusively to stress-management DTx. Applicable policies are spread across broader digital health and psychiatric-device documents. Guidance documents are often non-binding drafts subject to revision after public comment. Long-term effectiveness data for many DTx remain limited.

FAQ

When is a digital therapeutic for stress classified as an FDA-regulated medical device?
When it makes claims to treat, diagnose, mitigate or prevent stress-related psychiatric conditions rather than offering general wellness support. [1]

How do FDA policies differentiate wellness apps from regulated therapeutics?
Wellness apps without disease claims fall outside device regulation. Tools that assert medical benefits for behavioral health conditions require evidence and review. [1]

What regulatory pathways exist for marketing authorization of stress-management DTx?
Pathways depend on risk level and involve premarket review for devices that meet the medical definition, coordinated through the Digital Health Center of Excellence. [2]

Last updated: August 25, 2026